Member Info for JohnnyB1

RNS states "Current CFO Sath Nirmalananthan has indicated he will be leaving the Company and will step down from the Board of Directors as of April 24, 2026 to pursue other professional opportunities".

Looking at Scancell's accounts for year end 30 April'25, he holds options over 2 million shares (I million at 10.1 pence and 1 million at 11.7 pence). He has inside information about Scancell. If, as we all hope, Scancell are on the cusp of something brilliant, why would he simply leave to pursue other professional opportunities.

If this is the case surely he will loose his share options. The 20 May'24 and 20 February'25 Share Option RNS's both state "no vesting criteria other than to remain in employment"

I just don't understand it. Hopefully something will happen between now and when Sath leaves 24 April'26 that will make it worth Sath's while to exercise these options and we all can all get a piece of that cake.

Maybe we will get a RNS tommorrow.

Some will recall that Scancell updated the Advisory Board on their website. I noticed this on 22 March'26.

I believe the details were updated prematurely because Scancell removed these details the next day 23 March'26.

Scancell have now added these details again.

https://scancell.co.uk/about-us/

In June last year Phil said:-

“First and foremost at this stage Glymab Therapeutics is a wholly owned subsidiary of Scancell, as we have mentioned to create greater value from this antibody portfolio and capability.”

The wording "at this stage" fits in with a recent job advert posted by Genmab UK Limited (I mentioned this recently on here) this states "The Head of Medical Affairs, United Kingdom (UK) will lead the expansion and execution of Medical Affairs activities across the UK, as Genmab establishes a fully operational affiliate."

An affiliate is another type of relationship in the corporate world. Like a subsidiary, an affiliate is a company that is owned by another business entity. But unlike the subsidiary, the acquiring company owns between 20% and 50% of the affiliate's shares. (Just to be clear, I am no expert at this, I googled it).

If that "affiliate company" is Glymab Therapeutics Limited it could mean that Genmab UK Limited could acquire 20% to 50% of Glymab Therapeutics Limited.

If Genmab UK Limited acquires such a stake in Glymab Therapeutics Limited, those funds would then go to Scancell (With Scancell Shareholders still owning the remaining 50% to maximum 80% (depending on percentage Genmab UK Limited acquires) of Glymab Therapeutics Limited. I assume that Scancell could use those monies to fund the Phase 3 Scope Trial (i.e. going it alone as Phil mentioned) and/or the Modi 1 trial.

These are just my thoughts, I guess there are no end of possibilities. AIMHO

Scancell has now removed the details of the "Advisory Board". The "About us" page on their website now only shows "Management" and "Board of Directors".

Maybe someone released the details of the "Advisory Board" prematurely and has had to remove them?

I wonder if news is now imminent. Scancell has updated its Advisory Board on its website. It now consists of 10 people.

These include Georgina Long (Australia), individuals from the Netherlands, Germany, Italy and 3 people from the USA,

https://scancell.co.uk/about-us-2026/

CONTINUED

People and Team Development

Attract, develop, and retain top talent, fostering a culture of collaboration and excellence within the UK’s organization, while aligning with Genmab’s European values.

Provide mentorship and leadership to direct reports, drive superior performance, facilitate professional development, & cultivate future leadership talent ensuring their continuous development.

Champion innovation and direct change initiatives to benefit the business and enhance organizational effectiveness.

Exemplify Genmab’s culture and values, working as One Team.

Qualifications & Experience

MD, PharmD, or PhD in life sciences or a related discipline.

10+ years of experience in Medical Affairs within the pharmaceutical or biotech industry, with strong exposure to oncology.

Strong understanding of UK regulatory and health authority landscape, including MHRA, NICE, NHS England, SMC, and AWMSG, with proven experience engaging across HTA, access, and clinical governance frameworks. Familiarity with EMA processes and broader EU regulatory coordination preferred.

Proven record of accomplishment of success in product launches and early affiliate development.

Strong understanding of the UK’s healthcare landscape, oncology ecosystem, and regulatory environment.

Demonstrated ability to collaborate effectively within a matrix organization, balancing regional / global alignment and local execution.

Fluent in English (written and spoken).

Competencies & Attributes

Demonstrates strategic agility and innovative thinking, with the ability to operate effectively in a dynamic, high-growth biotech environment while maintaining scientific and operational rigor.

Strategic and analytical thinking with operational execution skills.

Strong cross-functional leadership.

Excellent communication and stakeholder engagement skills.

Deep scientific curiosity and a patient-focused ethos.

CONTINUED

Medical Strategy and Leadership

Develop and oversee the UK’s Medical Affairs strategy in alignment with European and global medical affairs strategic plans.

Act as the primary medical voice, ensuring that local insights inform national strategic priorities.

Serve as a member of the European Medical Affairs Leadership Team and UK Leadership Team contributing to the strategic direction & long-term vision of the department.

Collaborate closely with European Medical Affairs leadership and global strategy teams to provide United Kingdom perspective on opportunities, challenges, and stakeholder needs to ensure a consistent regional & global scientific narrative.

Scientific Communication & Evidence Generation

Provide the UK medical/scientific perspective with targeted insight compilation, analysis to inform clinical development & commercialization planning.

Oversee pan-portfolio investigator interactions to enhance medical/scientific exchange & optimize study execution across the UK.

Supervise dissemination & discussion of Genmab’s scientific/clinical data with investigators and other appropriate HCPs.

Develop and execute national conference plans, ensuring active participation in relevant professional society events.

Enable externally sponsored UK evidence generation initiatives.

External Engagement and Thought Leadership

Build and sustain relationships with UK’s top Key Opinion Leaders, healthcare and scientific communities, oncology networks, and scientific societies across Genmab’s areas of interest.

Represent Genmab at key local and regional medical congresses, symposia, and external scientific forums.

Partner with patient advocacy and policy organizations to strengthen Genmab’s presence as a trusted scientific collaborator.

Collect, analyse, and integrate medical and external insights to guide strategy, inform decision-making, and demonstrate the measurable impact of Medical Affairs in UK.

Launch Leadership

Partner cross functionally and drive launch readiness for the company’s first and subsequent commercial launches across the UK, ensuring robust scientific engagement, medical education, and field readiness.

Oversee launch readiness and lifecycle management across the region with evidence-based, patient-focused medical input.

Lead the development and localization of medical materials, delivery of local advisory boards, and execution of congress strategies.

Partner with MA Training to provide high-quality scientific training and maintain exceptional standards of scientific/technical expertise.

Compliance & Governance

Drive the implementation and continuous strengthening of local medical governance frameworks to ensure full compliance and operational excellence.

Partner to ensure appropriate review and approval of promotional and non-promotional materials to be used across the UK.

Collaborate with Pharmacovigilance and Regulatory Affairs to maintain product safety and compliance.

CONTINUED

Genmab UK Ltd have advertised a new Job Vacancy on linked-in for "Head of Medical Affairs UK".

What caught my attention is the references to affiliate e.g. "as Genmab establishes a fully operational affiliate". I was not sure what this meant so I googled it and found that "An affiliate can be a company in which another company owns a minority stake or a business connected through a formal relationship without full ownership":-

About the job

At Genmab, we are dedicated to building extra[not]ordinary® futures, together, by developing antibody products and groundbreaking, knock-your-socks-off KYSO antibody medicines® that change lives and the future of cancer treatment and serious diseases. We strive to create, champion and maintain a global workplace where individuals’ unique contributions are valued and drive innovative solutions to meet the needs of our patients, care partners, families and employees.

Our people are compassionate, candid, and purposeful, and our business is innovative and rooted in science. We believe that being proudly authentic and determined to be our best is essential to fulfilling our purpose. Yes, our work is incredibly serious and impactful, but we have big ambitions, bring a ton of care to pursuing them, and have a lot of fun while doing so.

Does this inspire you and feel like a fit? Then we would love to have you join us!

The role

The Head of Medical Affairs, United Kingdom (UK) will lead the expansion and execution of Medical Affairs activities across the UK, as Genmab establishes a fully operational affiliate. Reporting directly to the European Medical Affairs organization, the incumbent will serve as the senior medical affairs leader in the UK, responsible for shaping the national medical strategy to deliver the company’s first launch together with further expansion of a strong existing research footprint, whilst ensuring continued alignment with regional and global priorities.

This role offers a unique blend of strategic leadership and hands-on execution in a biotech environment characterized by agility, innovation, and scientific depth. The role will be pivotal in ensuring that medical excellence underpins all affiliate activities, while also representing the United Kingdom within Genmab’s broader European and Global organizations.

Affiliate Partnership & Cross-functional Collaboration

IAct as a strategic medical partner to the UK General Manager and cross-functional leadership team, ensuring full compliance with MHRA regulations, NHS governance standards, and local pharmacovigilance requirements.

Ensure scientific and ethical rigor in all affiliate activities, collaborating effectively with Marketing, Market Access, Commercialization, Legal, QA, Regulatory, and other Research & Development and Enabling functions.

Establish and track clear medical performance metrics (KPIs) and ensure readiness for quarterly business reviews to drive accountability and continuous improvement.

CONTIN

I listened to it and to be honest I found it very scientific and way over my head.

I too felt Phil did not have a lot to say, even when asked directly at the end of the webinar.

I feel that, given the scientific nature of the discussion, Lindy would have been far better suited to represent Scancell.

GEN1079 may or may not be one of Scancell's antibodies, we simply do not know (we also do not know the trigger for the first milestone payment, it could for example be "first patient dosed"). However it is worth mentioning that the status of this trial changed to "Recruiting" yesterday (From "Not yet recruiting"). At least this demonstrates that Genmab don't drag their feet which is definitely in our interest:-

https://clinicaltrials.gov/study/NCT07387068

My thoughts are that GEN1079 is either Scancell's antibody or Oxford Biotherapeutics OBT700R (They entered a licence agreement with Genmab 3 October 2022 very shortly before Scancell's licence agreement 25 October 2022).

https://www.oxfordbiotherapeutics.com/pipeline?partnership=partnered

If you look at page 4 of Scancell's interim results presentation you will see that Scancell's 2 antibodies partnered with Genmab (SC129 and SC2811) both state "indication" "Solid Tumours":-

https://scancell.co.uk/wp-content/uploads/2026/01/Scancell-Interims-FY26-Presentation_FINAL2.pdf

I see that Genmab has a "New", " Not yet recruiting" Phase 1 (antibody) "Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors":-

https://clinicaltrials.gov/study/NCT07387068?term=Genmab&page=1&rank=2

It may not be anything, but on the other hand might it be one of Scancell's antibodies?

Scancell worked incredibly hard to get the IND in before Christmas; I have never known them commit so much to a deadline.

We know from the presentation that there is a strong Global IP until 2041. We also know that the market for Unresectable Melanoma is estimated at $3 Billion Dollars per annum. 2041 may be a long way off, however every one month delay in starting the trial will effectively cost $250 Million Dollars (one twelfth of $3 Billion) in potential lost revenue.

Regardless of whether Scancell go it alone or with a partner I believe they are going to want to get the trial started ASAP. I don't think it will be long before we know the way forward AIMHO

30 minutes into the webinar Sath says "We do have upside on this run way too, namely the development milestones from SC129 anticipated this calendar year"

So that is milestones in the plural (not singular) from SC129. I wonder what triggers the milestones, maybe FDA clearance of an IND application for a Phase 1 trial, maybe also first patient dosed?

Looking back at the original RNS concerning SC129 (dated 25 October 2022) this states:-

"Scancell to receive from Genmab an upfront payment as well as potential milestone payments of up to $208 million for each product developed and commercialised, up to a maximum of $624 million if Genmab develops and commercialises products across all defined modalities."

So say Genmab starts SC129 trials in 3 separate "products" this year does that mean 3 separate milestone payments (one for each product) could be received in 2026?

Phil said that when they submit the IND, before the end of the year (2025), "along with that we will start to ask, particularly the FDA, questions around can we get a breakthrough status given the data and what is the possibility to even get an accelerated approval which helps our commercialisation timeline so great momentum with the regulators to date". It is 28 minutes into the following presentation:-

https://vimeo.com/1145685960?share=copy&fl=sv&fe=ci

It would certainly make a great RNS if we got breakthrough status and accelerated approval.

Matt Kiely made the following post on Linkedin today. The third paragraph is interesting:-

Since joining @Genmab earlier this year, I’ve had the privilege of witnessing the energy, ambition and purpose that drive our work in the United Kingdom. As 2025 draws to an end, it feels like the right moment to reflect on the foundations we’ve laid and the momentum we’re building.

One standout milestone has been the opening of our new London office. It marks an important step in strengthening our presence in the UK and advancing our mission to make a meaningful difference for more patients. I’m also excited to welcome more colleagues into the space as we continue to grow our team.

Another highlight was bringing our cross-functional teams together in London for one of our ongoing planning sessions. The collaboration and shared focus across functions reflected the strength of Genmab’s culture and the opportunities ahead as we deepen our engagements across the UK’s scientific, clinical and health innovation communities. It’s been truly inspiring to experience how Genmab’s purpose – transforming the lives of patients through antibody innovation – connects so strongly with the conversations shaping the future of healthcare in the UK.

A huge thank you to everyone who has supported our work during these first few months. Your energy, partnership and commitment are laying the groundwork for an exciting chapter ahead.

Wishing you all a wonderful festive season. I’m looking forward to continuing our collaborations in 2026.

The presentation is now on Scancell's website:-

https://scancell.co.uk/wp-content/uploads/2025/12/SCOPE-data-update-presentation-11-December-2025.pdf

Callum says "manufactured, tested, and released a commercial-scale batch of drug substance suitable for clinical use".

I don't know but can only assume that "released" means released to the clinical trial sites; whether that's just UK or also USA and Europe? They would have to be pretty certain to take delivery; it would not be a case of "park round the back mate and unload them".

Hi Bermuda, thank you for your post 10 Nov. 20.35.

I see that the speaker is Kate Young and she is the SCOPE study contact at the Royal Marsden NHS Foundation Trust:-

https://clinicaltrials.gov/study/NCT04079166?cond=Melanoma%20Metastatic&term=SCOPE&rank=1

Kate is not a Scancell employee; I am just wondering whether it is unusual for a non employee to present a Scancell poster? She will of course have first hand experience of dealing with patients on the existing SCOPE trial so perhaps it is linked to the Cancer Vaccine Launch Pad and promoting the next stage in the SCOPE trial?

More SCOPE and ModiFY data at ESMO 2025 10-12 December'25; according to this post by Pietro Tansini of RIVIA on Linked-in:-

"One thing is to talk about your partners, another is when your partners talk about you.

That’s what happened last week, when Dr. Nermeen Varawalla brought RIVIA on stage at hashtag#SITC25 while presenting new data from one of their Phase 2 cancer vaccine trials.

We’ve followed Scancell’s team and their tireless work on SCOPE and ModiFY studies since last year, when Dr. Nermeen first met Rivia at hashtag#ESMOImmuno24.

And we’d also like to echo Nermeen’s praise for Georgia Goodhew, Joe Thornton, Robert Miller, Joe Chadwick, Samantha Paston, and Lindy Durrant for the great work that went into these results.

It’s incredibly gratifying to help advance programs as impactful as this one.

We’re looking forward to seeing more data from these studies at hashtag#ESMOImmuno25 in London next month.

RIVIA will be there too! Reach out if you’d like to hear how modern biotechs like Scancell are using unified Trial Intelligence to run their trials more efficiently and move faster."

Sorry, to get the right image you may need to copy and paste the whole link:-

https://thevendry.com/venue/164140/***lord-national-resort-convention-center-oxon-hill-md/space/34600